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Abstract
Purpose: The main purpose of this study is to (1) identify the continual diversitybetween conventional fixed field intensity modulation radiotherapy (IMRT) andRapidArc (RA) for high-risk prostate cancer; and (2) determine potential benefitsand drawbacks of using for this type of treatment. Methods: A cohort of 20prostate cases including prostate, seminal vesicles and pelvic lymph nodes wasselected for this study. The primary planning target volume (PTVP) and boostplanning target volume (PTVB) were contoured. The total prescription dose was75.6 Gy (45 Gy to PTVP and an additional 21.6 Gy to PTVB). Two plans weregenerated for each PTV: multiple 7-fields for IMRT and two arcs for RA. Results: ASigma index (IMRT: 2.75 ± 0.581; RA: 2.8 ± 0.738) for PTVPand (IMRT: 2.0 ± 0.484;RA: 2.1 ± 0.464) for PTVB indicated similar dose homogeneity inside the PTV.Conformity index (IMRT: 0.96 ± 0.047; RA: 0.95 ± 0.059) for PTVPand (IMRT: 0.97± 0.015; RA: 0.96 ± 0.014) for PTVB was comparable for both the techniques. IMRToffered lower mean dose to organ at risks (OARs) compared to RA plans. Normaltissue integral dose in IMRT plan resulted 0.87% lower than RA plans. All the plansdisplayed significant increase (2.50 times for PTVP and 1.72 for PTBB) in theaverage number of necessary monitor units (MUs) with IMRT beam. Treatmentdelivery time of RA was 2 ‒ 6 minutes shorter than IMRT treatment. Conclusion:For PTV including pelvic lymph nodes, seminal vesicles and prostate, IMRT offereda greater degree of OARs sparing. For PTV including seminal vesicles and prostate,RA with two arcs provided comparable plan with IMRT. RA also improved thetreatment efficiency due to smaller number of MUs required.
Keywords: IMRT, RapidArc, Sigma-Index, Conformity Index, Normal TissueIntegral Dose
1. IntroductionCancer is the major cause of leading deaths in the 21stcentury in world with 14.1 million cases and 8.2 milliondeaths in 2012.1Among them, prostate cancer stands asimportant due to risk of secondary malignanciesassociated with intensity modulation radiation therapy(IMRT) with conventional 3-dimentional conformalradiotherapy (3D-CRT).2 Among the differenttechnologies adopted to cure the prostate cancer,external radiotherapy is recognized as one of the
important treatment options.3-4 The technology aims todestroy cancer cells by minimal damaging (due to risk ofsecondary malignancies) to the surrounding normaltissues. It creates the best possible balance betweenmaximizing dose to prostate cancer cells andminimization of side effects. IMRT technology forprostate tumor/cancer allows less toxicity incomparison to 3D-CRT.5 The development of IMRTtechnique has enabled the delivery of highly conformal
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dose distribution to the target while limiting radiationdamage to the critical organs within the tolerance limit.For the prostate cancer treatment, IMRT has been anideal technique with the geometric relationship of thetarget volume to bladder, rectum and surroundingnormal tissue.RapidArc (Varian Medical Systems, Palo Alto, California,USA) is a volumetric radiotherapy technology thatdelivers a fast and precise sculpted 3D dose distributionwith a single 360-degree rotation of the linearaccelerator gantry to improve the standard of care andtreatments.6 It is made possible by a treatment planningalgorithm that simultaneously changes 3-parametersduring treatment by tuning rotation speed of the gantry;shape of the treatment aperture using the movement ofmultileaf collimator leaves and delivery dose rate.Volumetric modulated arc therapy differs from existingtechniques like helical IMRT or intensity-modulated arctherapy (IMAT) because it delivers dose to the wholevolume, rather than segment by segment. Thetreatment- planning algorithm ensures the treatmentprecision and helping to spare normal healthy tissue. 7Some of the studies were performed for the prostatecancer treatment; however, they included prostate onlyor prostate with seminal vesicles.8 The present studyaims to expand such studies to identify the main andcontinual diversity between two techniques for prostatecancer cases that involve the seminal vesicles and pelviclymph nodes. The dosimetric results and treatmentdelivery efficiency using the RapidArc technique werecompared to those using the conventional static-gantryIMRT technique.
2. Methods and MaterialsA cohort of 20 high-risk prostate cancers patientsincluding prostate, seminal vesicles, and pelvic lymphnodes were selected for our study. Computedtomography (CT) images were acquired with an emptyrectum and full bladder for all patients. The attendingradiation oncologist manually segmented prostate,seminal vesicles, and nodes based on the CT images. Theprimary planning target volume (PTVP) was defined toinclude a 1.0 cm margin around the pelvic lymph nodesin all directions plus a 0.7 cm margin around prostate,and seminal vesicles in all direction except the posteriordirection, where 0.5 cm margin was added. The boostplanning target volume (PTVB) was defined to include
0.7 cm margin around the prostate and seminal vesiclein all direction except the posterior; where 0.5 cmmargin was added.Rectum, bladder, bowel, left and right femoral head werecontoured as organ at risk (OARs) based on CT images.In all the patients, anterior-posterior (AP) and lateralseparation were very close. The average AP diameterswere 21 cm and the lateral diameters were 34 cm. Theaverage volume of PTVP and PTVB were 534.47 cc(range, 860.10 cc-360.00 cc) and 163.50 cc (range, 181cc-148 cc), respectively. The average volume of bladder,rectum, right femoral head, left femoral head and bowelwere 223.51 cc (range, 87.21 cc-360.32 cc), 68.61 cc(range, 42.91 cc-111.60 cc), 53.51 cc (range, 68.13cc-40.31 cc), 53.47 cc (range, 37.90 cc-63.81 cc) and1243.90 cc (range, 380 cc-1680 cc), respectively. For thisstudy, we have followed Radiation Therapy OncologyGroup (RTOG-0521) protocol. The total prescriptiondose was 75.6 Gy with a daily dose of 1.8 Gy. Theprescription dose of the primary plans was 45 Gy and anadditional 30.6 Gy to boost plan. Two arcs (182o to 178o;178o to 182o) were used in both clock wise andanti-clock wise directions for all patients in RapidArctreatment planning.9 For the clockwise arc, thecollimator was rotated 20o, whereas for theanti-clockwise arc, the collimated was rotated 340o inorder to reduce the effect due to inter-leaf leakage.Seven fixed fields with angulations of 0o, 51o, 102o, 153o,207o, 2080, and 309o with dynamic leaf were used forIMRT. All plans were generated using Eclipse treatmentplanning system (version 8.0.15) by a single user onlyand the volumetric dose optimization method followedthe same systematic strategy regarding the objectiveand priorities. Dose grid sizes of (2.5×2.5×2.5) mm3 andthe anisotropic analytical algorithm (AAA) were used inthis study. The slice thickness of the CT images used forplanning purpose was 3 mm. Both IMRT & RapidArcplans were developed for each patient using 6 MV10photons with maximum dose rate of 600 MU/min in aVarian made Novalis Tx machine; having dynamiccapability of 120 high definition Multi leave collimator(MLC). The optimization constraints9 for all plans arelisted in Table 1. These constraints and weightings wereset initially and then modified by either relaxing ortightening during the optimization process based on thereal-time updated dose-volume histograms (DVHs) ofstructures.
Table 1: Dose-Volume constraints and relative weightings used for optimization of both FB and FFF RapidArc plans.PTVs and OARs Dose-Volume constraints Relative weightingPTVPand PTVB D100≥98%;Dmax≤102% 120-130Rectum andBladder V70%≤30%; V50%≤50%; V30%≤70%;D5-D10≤total of60-70Gy;Dmax≤100% 60-80Bowel V50%≤30%; V30%≤50%; V10%≤70%;Dmax≤total of 45Gy 50-60Femoral heads V20%-V30%≤30%; Dmax≤total of 45Gy 40-50
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2.1 Sigma index (S-index) and conformity index
(CI)Treatment planning was done based on the radiotherapyobjective of delivering a therapeutic dose to awell-defined target while minimizing dose to thesurrounding normal tissue and critical organs. Itrequires optimization of conformity of the prescriptiondose to the planning target volume, dose homogeneitywithin the PTV, dose to the surrounding normal tissueand critical organs. The following parameters wereevaluated for comparing cumulative DVH of the patientsuch as Sigma-index, conformity index, and mean dosesto the bladder, rectum, bowel, right femoral head, andleft femoral head.A better representation of homogeneity could be definedin term of sigma index (S-index).11 This uses thedifferential DVH, unlike other indices, which iscumulative DVH. S-index is a measure of the standarddeviation of the doses about the mean dose. The S-indexis expressed as:
i
SD i mean
vS index D (D D ) V    Dmean is the mean dose of the target (PTV in this study)curve. Di is dose to the ith bin having a volume vi. V =total volume of the target.The conformity index (CI) was defined to compare thetreatment plans. The conformity index is defined as theratio of the 95% isodose volume divided by the PTV thatis enclosed by the 95% of the isodose line. From thisdefinition, as the conformity index approaches 1, themore conformal is the treatment plan.
2.2 Dose distribution, PTV coverage and organs at
riskIn addition to providing information on the homogeneityof radiation doses, DVHs can be used to assess the targetcoverage index, defined as the percentage of the tumorvolume that received the prescribed dose. Ideally, tumorDVH would be a step function, with 100% of the targetreceiving the exact prescribed dose. However, actualDVH curves are not step functions, because ofconstraints imposed by tumor volume and other OAR.Rules for the PTV was set such that the prescribed dosecovered at least 95% of the PTV (D95) and the PTVvolume receiving >107% of the prescription was limitedto 2% in line with ICRU report 50 and ICRU report 62.To achieve this objective, a constraint for D100 was set toreceive ≥98% of prescription and constraint formaximum dose (Dmax) was set to receive ≤102% of theprescription in the optimization process for both plans.The volumes that received a minimum of 70 Gy, 60 Gy,40 Gy, (V70Gy, V60Gy, V40Gy,) for rectum, 70 Gy, 60 Gy, 40Gy, (V70Gy, V60Gy, V40Gy,) for bladder and 45 Gy, 15 Gy
(V45Gy, V15Gy) for bowel, respectively, were selected toevaluate volumes of high dose.12-13
2.3 Normal tissue integral dose and MUThe integral dose (in unit of liter-Gy) was defined as theabsorbed dose integrated over the voxels in the entirevolume excluding the PTV. The integral dose (ID) (meandose × tissue volume) received by normal tissue (NTID)
14 was calculated from dose-volume histograms. Forcomparison, the integral dose ratio was obtained bydividing the integral dose from IMRT plan by theintegral dose from RapidArc plan. MU was analyzed forIMRT and RapidArc plans.
2.4 Statistical analysisStatistical analysis was performed with StatisticalAnalysis Software (SAS), version 9.3. Mean values andstandard deviation of the mean (SD) were collected.Relative dosimetric changes were compared applyingthe paired t-test. A two-sided p-value ≤ 0.05 wasconsidered statistically significant. Confidence intervalsincluded 95% of the measured data.
3. Results
3.1 Sigma index (S-index) and conformity index
(CI)The S-index and conformity indices for all the prostatepatients in the both IMRT and RapidArc plans with 6 MVphotons are analyzed. The relative efficacy (IMRT/RapidArc) values for, S-index and conformity index are0.9832, 1.010 for PTVP and 1.0, 1.005 for PTVBrespectively. Table 2 shows S- index and conformityindex of both IMRT and RapidArc Plans in all type ofPTVs.
Table 2: S- index and Conformity index of both IMRT andRapidArc Plans in all type of PTVs.Technique SI CIPTVP IMRT 2.35±0.581 0.96±0.047PTVPRapidArc 2.39±0.738 0.95±0.059PTVB IMRT 2.1±0.484 0.979±0.015PTVBRapidArc 2.1±0.464 0.975±0.014
3.2 Dose distribution, PTV coverage and organs at
riskIn this study, we analyzed a total of 80 prostate cancertreatment plans of 20 patients. The clinical dosimetricimpact of IMRT, in comparison with RapidArc, wasassessed. Transversal view of comparative dosedistribution between IMRT plan (left side) and RapidArcplans for PTVP (right side) for prostate cancer withlymph nodes involved is shown in Figure 1. A typicalDVHs for 6-MV plans (IMRT and RapidArc) arecompared in Figure 2.
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Figure 1: Transversal view of comparative dose distribution between IMRT plan (Left Side) and RapidArc plans for PTVP(Right side) for prostate cancer with lymph nodes involved.
Figure 2: Comparison of the dose -volume histograms for IMRT (square) and (triangle) for RapidArc plan for the case shownin Figure 1.
Table 3:Mean dose statistics (with SD) of organ at risk for composite plan.Structure Dose-volumeconstraints Volume achieved in %IMRT RARectum V70 < 30% 63.0±5.9% 69.4±4.4%V60 < 50% 50.0±4.1% 57.4±3.0%V40 < 70% 38.2±3.3% 39.5±2.6%Bladder V70< 30% 63.3±10.2% 69.4±9.4%V60< 50% 45.0±7.4% 49.5±7.7%V40< 70% 33.0±5.6% 38.0±5.8%Bowel V45Gy< 195cc 4.49±1.08% 5.00±1.09%Rt. femoral head V50Gy < 5% 0.0±0.0% 0.0±0.0%Lt. femoral head V50Gy< 5% 0.0±0.0% 0.0±0.0%
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For the rectum, there were dose differences between thetwo treatment modalities in the volume exposed to 70Gy, 60 Gy, and 40 Gy are 10%, 14.8% and 3.4%,respectively, which is statistically significant (p <0.0001). In case of bladder, there were dose differencesfor the volume exposed to 70 Gy, 60 Gy and 40 Gy are9.63%, 10% and 15%, respectively, which is statisticallysignificant (p < 0.0001). For the bowel, there were nosignificant dose differences between two treatmentmodalities in the volume exposed to 45 Gy or 15 Gy, andfemoral heads were within the required constraints forall patients. Table 3 shows mean dose statistics withstandard deviation of organ at risk for composite plan.Table 4 shows the average maximum dose statistics(with SD) and average dosimetric indices with standarddeviation of PTV and organ at risk for composite plan.There were significant differences between IMRT andRapidArc plans for the average doses delivered to thebladder and rectum. A significant increase in mean doseof 12% (p < 0.0002, 95% CI = 0.7714 to 2.2312) to therectum and 15.4% (p < 0.0001, 95% CI = 4.294 to 6.771)for bladder was measured for RapidArc plans comparedwith IMRT plans. For the bowel, there was no significantdose difference between two treatment modalities in theaverage doses and femoral heads were within therequired constraints for all patients. The averagemaximum dose of PTV is 106.7% and 105.7% ofprescribe dose for both IMRT and RapidArc plans,respectively and different was significant (p < 0.0002,95% CI = 45.49 to 127.5). No significant differences
between two modalities were observed with respect tomean average maximum dose to bladder, rectum,femoral heads, and bowel.
3.3 Normal tissue integral dose (NTID) and MUNTID was used as an index to compare techniques forradiation induced second cancers. The NTID (mean ±SD) was 182.07 ± 46.07 liter-Gy for IMRT plan and183.65 ± 47.26 liter-Gy for RapidArc plans. RapidArcplans produced 0.87% (p < 0.044, 95% CI = 0.045 to3.113) more dose compared with the IMRT beam, andthis difference is not significant. Comparison of theintegral dose for IMRT and in RapidArc composite plansis shown in Figure 3. We found that MU (mean ± SD) was1542 ± 239 for IMRT plans and 618 ± 71 for RapidArcplans in PTVP. MU (mean ± SD) was 1041 ± 195 for IMRTplans and 605 ± 78 for RapidArc plans in PTVB.Compared with RapidArc plans, the MU significantlyincreased by 2.50 times (p < 0.0001, 95% CI = 368.7.49to 502.3) in PTVP and 1.72 times (p < 0.0001, 95% CI =846.4 to 998.2) in PTVB for IMRT plans shown in Figures4-5. The beam–on time of PTVp was 4.2 min to 4.3 minfor IMRT and 2.1 min to 2.3 min for RapidArc; whereasfor PTVB , it was 2.5 min to 2.6 min for IMRT and 1.0 minto 2.3 min for RapidArc. Treatment time of PTVp was 8.1min to 8.2 min for IMRT and 3.1 min to 3.2 min forRapidArc; whereas for PTVB, it was 5.1 min to 5.2 minfor IMRT and 3.1 min to 3.2 min for RapidArc. Thetreatment time of RapidArc was 1.5 times shorter thanIMRT for PTVp but approximately same in PTVBplans.
Table 4: Average maximum dose statistics (with SD) and average dosimetric indices (with SD) of PTV and organ at risk forcomposite plan.Structure Mean dose in Gy Maximum dose in GyIMRT RA IMRT RAPTV 76.50±0.82 76.50±0.72 80.89±1.31 80.13±0.93Rectum 37.9±4.75 42.7±4.59 76.44±.68 77.77±.75Bladder 35.7±11.86 41.2±12.0 79.46±0.56 78.92±0.66Bowel 23.0±2.89 23.08±2.84 45.6 ±24.2 45.7±23.6RT FH 24.5±1.88 25.3±1.82 47.47±4.44 49.35±5.13LT FH 24.4±1.85 25.2±1.97 47.86±4.60 50.51±6.02
Figure 3: Comparison of the integral dose for IMRT and RapidArc composite plans.
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Figure 4: Comparison of the MUs for IMRT and RapidArc plans for PTVP (primary planning treatment volume).
Figure 5: Comparison of the MUs for IMRT and RapidArc plans for PTVB (Boost planning treatment volume).
4. DiscussionIt clearly represents that there is no significantdifference of homogeneous index for both the PTVs inIMRT and RapidArc plans. From our data between IMRTand RapidArc plans, IMRT plans are showing lowerS-indices for both PTVP and PTVB plans indicatingimproved dose homogeneity compared to RapidArcplans. However, target inhomogenity (defined asDmax-Dmin) was increased by 12.3% (p < 0.0001, 95%CI = 2.256 to 3.677) for IMRT compare with RapidArccomposite plans. For IMRT plans, target inhomogenity issignificantly increased for PTVp compared to RapidArcplans because of lymph nodes involvement with PTVP.However, in PTVB, inhomogenity is comparable for bothplans.Miften et al.15 have demonstrated the use of targetconformity index (TCI) and normal tissue-sparing index(NTSI) to assist in the process of judging the merit of aclinical treatment plan. However, in this work, thewidely accepted conformity index was used to evaluatethe conformity of the treatment plans (Table 2) for allthe patients using both techniques. The meanconformity index was 0.96 and 0.95 for PTVPand 0.979and 0.975 for PTVB in both IMRT and RapidArc plans,
respectively. These small differences indicate that theseplans are nearly identical in their conformity of dose tothe target. However, there is difference observed inbetween PTVs. For PTVP, conformity index is lowervalues than PTVB plans due to involvement of lymphnodes. Sua et al.16 reported similar results in theirplanning study for PTVs involved with pelvic lymphnodes.Rectum and bladder are showing high dose for RapidArcplans comparable to IMRT plans. This dose variationwas significantly increased in PTVp compared to PTVB.Sua etal.16 reported that IMRTplans with PTVP showedbetter sparing of bladder, rectum, and small bowel than2 arcs plans. Kjaer-kristoffersen et al.17 noted larger OARdoses with RapidArc than IMRT plans while prostateand seminal vesicles were considered as PTVs.Because radiation could induce second malignancies18,
19, integral dose was used as an index to evaluatetreatment plans. In our study, integral dose index(IMRT/RapidArc) is 0.99, which is very negligible. Sua et
al.16 reported that 7% to 8% greater integral dose inRapidArc than in IMRT which is not confirmed in ourstudy. Palmer et al.20 noted larger integral doses withIMRT than with IMAT based on MU values for prostate
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cancer which is conflict with our findings. Integral doseis related not only to MUs but also to other complicatedfactors. The combination of MUs, correspondingaperture sizes and shapes, target volumes and shapescontributes to integral dose.16 In the primary plans, MUswas approximately 60% greater than in RapidArc plans.In boost plans, the average values of total MUs in IMRTplans was approximately 42% greater than in RapidArcplans.The IMRT planning was performed in Eclipse treatmentplanning system using Novalix Tx Linac and 120HD MLC,which have a limit that MLC cannot travel beyond 14 cmduring beam delivery. To overcome this limit, a largeIMRT beam is split into two or three subfields, which areplanned and calculated as one beam but delivered astwo or three separate beams.16 Without this limitation,IMRT delivery time could be reduced by approximately1.2 min for a prostate cases that include the lymphnodes. The mean delivery time of IMRT was longerowing to the larger number of beams, the dead time inthe gantry rotation from field to field and the largernumber of MUs delivered. The shorter treatment time ofRapidArc is beneficial to the patient, as it would helpreduce the time the patients required to maintain a fullbladder status. Shorter treatment time does not onlyreduce the probability of the intra-fractional motion ofpatients, but it can also decrease the impact of internalorgan motion on the treatment delivery.21 The shortertreatment time of RapidArc would be welcomed by busycenters and shorten the patient waiting list.Although our study focused on photon therapy, protontherapy is also another option to treat the prostatecancer in external beam radiotherapy.22, 23 Protontherapy can produce excellent dose distribution becauseprotons have finite range and sharp distal fall-off at theend of proton beam path. Vargas et al.24 and Rana et al.25demonstrated that proton therapy is better at sparingrectum and bladder when compare to the photontherapy.
5. ConclusionIn this study, the clinical dosimetric impact of IMRT, incomparison with RapidArc, was assessed for prostatecancer patients. For complicated and large PTVs thatincluded prostate, seminal vesicles and lymph nodes,conventional IMRT spared the bladder, rectum dosesbetter than did RapidArc. For simple and small PTVs thatincluded prostate and seminal vesicles, RapidArc planswere comparable to those achieved with conventionalIMRT plans. The integral dose was more in RapidArc butnot significant. The treatment delivery efficiencyimproved with RapidArc plans. RapidArc plans shouldbe compared with IMRT plans for individual cases tomeasure gains and losses before selecting one over theother. Clinical studies are required to evaluate its clinicalbenefits.
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